JPY1,460.00
0.14% today
Tokyo, Mar 13, 07:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Stock price

JPY1,458.50
-35.50 2.38% 1M
-246.50 14.46% 6M
-76.00 4.95% YTD
-125.00 7.89% 1Y
-434.00 22.93% 3Y
-120.50 7.63% 5Y
-536.00 26.87% 10Y
Tokyo, Closing price Thu, Mar 13 2025
+0.50 0.03%
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key metrics

Market capitalization JPY2.61t
Enterprise Value JPY3.46t
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 25.56
EV/Sales (TTM) EV/Sales 1.85
P/S ratio (TTM) P/S ratio 1.40
P/B ratio (TTM) P/B ratio 1.75
Dividend yield 5.08%
Last dividend (FY25) JPY74.00
Revenue growth (TTM) Revenue growth 21.01%
Revenue (TTM) Revenue JPY1.87t
EBIT (operating result TTM) EBIT JPY231.07b
Free Cash Flow (TTM) Free Cash Flow JPY135.48b
Cash position JPY179.87b
EPS (TTM) EPS JPY-32.05
P/E forward 417.91
P/S forward 1.38
EV/Sales forward 1.83
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Astellas Pharma forecast:

4x Buy
33%
7x Hold
58%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Astellas Pharma forecast:

Buy
33%
Hold
58%
Sell
8%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,867,631 1,867,631
21% 21%
100%
- Direct Costs 482,425 482,425
35% 35%
26%
1,385,206 1,385,206
17% 17%
74%
- Selling and Administrative Expenses 624,773 624,773
9% 9%
33%
- Research and Development Expense 329,275 329,275
15% 15%
18%
431,158 431,158
32% 32%
23%
- Depreciation and Amortization 200,092 200,092
51% 51%
11%
EBIT (Operating Income) EBIT 231,066 231,066
19% 19%
12%
Net Profit -57,427 -57,427
99,112% 99,112%
-3%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today